MTF Biologics Launches FlexHD Pliable PRE for Pre-Pectoral Breast Reconstruction

MTF Biologics expands its portfolio of innovations for post-mastectomy breast reconstruction with the launch of an acellular dermal matrix (ADM) designed specifically for pre-pectoral breast reconstruction procedures: FlexHD Pliable PRE.

Made from a proprietary process for faster integration, and fenestrated to conform and project naturally, the unique design of FlexHD Pliable PRE aims to minimize preparation time in the operating room.

FlexHD Pliable PRE was introduced during Plastic Surgery The Meeting, September 28-October 1, 2018, at McCormick Place West in Chicago.

“The pre-pectoral breast reconstruction procedure is becoming more popular because it can mean a shorter surgery, less pain and reduced recovery time for patients when compared to other methods,” says Tom Shaffer, executive vice President, global sales & marketing, at MTF Biologics, in a media release from the company.

“In talking with Plastic and Reconstructive Surgeons across the nation, it became clear that a new tissue form designed specifically for the pre-pec procedure would be useful. So, we teamed up with surgeons advancing this area of practice to examine how we could better serve that need, and with their feedback and guidance, FlexHD Pliable PRE was born.”

The pre-pectoral breast reconstruction procedure is the latest advancement in post-mastectomy breast reconstruction. As part of the procedure, an implant is placed over the chest muscle directly under the skin as opposed to under the muscle as is common in most reconstruction procedures. This method eliminates the need to cut into the muscle which may mean a shorter procedure in many cases as well as less pain during recovery, and less animation deformity in the reconstructed breasts longer term.

FlexHD Pliable PRE is designed to support and conform to the breast pocket, starting as a two-dimensional pattern that transforms into a three-dimensional shape to promote aesthetic symmetry.

“With bilateral pre-pectoral breast reconstruction, time and attention is needed to achieve proper projection and symmetry,” states Aldona Spiegel, MD, board certified plastic and reconstructive surgeon and director and founder of the Center for Breast Restoration at the Institute for Reconstructive Surgery at The Methodist Hospital in Houston, who is the innovator of the design.

“FlexHD Pliable PRE can be used as a template for both breasts improving symmetry and efficiency in the OR, helping to achieve more natural results.”

[Source: MTF Biologics]

Applications Now Open for Allograft Tissue Research Grant Program

The Plastic Surgery Foundation (PSF) and MTF Biologics are now accepting applications for their Allograft Tissue Research Grant Program. A collaborative effort from The PSF and MTF Biologics that began in 2013, the program funds applied research on biologic reconstruction to enhance patient care. The deadline for submissions is December 3, 2018.

“To develop new clinical approaches and advance positive patient outcomes in plastic and reconstructive surgery, we need a constant stream of new research in the field,” says Arun Gosain, MD, president of The PSF, in a media release. “We are pleased to continue this partnership with MTF Biologics to fund the critical work of clinicians and scientists seeking to uncover new ways that human tissue can advance patient care and results.”

MTF Biologics has committed $1 million to The PSF/MTF Biologics Allograft Tissue Research Grant Program through 2021, and selected applicants may receive up to $100,000 to support 1- to 2-year research projects advancing the use of allograft technologies in plastic and reconstructive surgery. Supported research must include a strong clinical translation component that incorporates dermal, adipose, placental or other allograft transplant technologies.

“Through our partnership with The Plastic Surgery Foundation, we have been able to foster more opportunities for biological reconstruction research,” said Marc Long, PhD, vice president of R&D at MTF Biologics. “We are proud to partner with an organization that shares our mission of supporting surgeon-scientists and healthcare providers who are seeking new ways to save and heal lives.”

Over the last 5 years, The PSF/MTF Biologics Allograft Tissue Research Grant Program has funded projects from clinicians and researchers at institutions including University of Texas M.D. Anderson Cancer Center, University of California, Massachusetts General Hospital, University of Pittsburgh, and Memorial Sloan-Kettering Cancer Center, among others.

Recent funded projects include:

  • Optimizing Adipose Stem Cell Immunotherapy through Cell-Assisted Lipotransfer
  • Tissue-Engineered Lymph Node Transplantation for the Treatment of Lymphedema
  • Activated Adipose Stem Cells for the Prevention/Treatment of Diabetic Foot Ulcers
  • Tissue Engineered 3-D Ear Cartilage Construct
  • Skin Improvement in Radiation Wounds: The Impact of Adipose Derived Stem Cells
  • Perfusion Decellularized Skin Flap as a Dermo-Epidermal Scaffold
  • Bio-patterned DermaMatrix to Induce Islet Cell Allograft Tolerance
  • Evaluation of Human Acellular Dermal Matrix in Joint Arthroplasty

“Since 1987, MTF Biologics has given more than $50 million in grants to fuel important advances in regenerative medicine and serve as a driving force in creating research opportunities that advance the science of tissue transplantation,” states Jeffrey Cartmell, PhD, associate director of intellectual property & grants at MTF Biologics. “Prior grant recipients have produced exceptional work in their respective fields, and we look forward to funding the next generation of scientists as they uncover new solutions to improve patient care.”

Applications for the 2019 PSF/MTF Allograft Tissue Research Grant Program close on December 3, 2018.

For more information and to apply, visit The Plastic Surgery Foundation or email

[Source(s): The PSF, MTF Biologics]